As shown in Fig. 3F, G, osimertinib reduced tumor volumes in both groups, while the final tumor volume inhibition revealed that CAMSAP3 knockdown significantly increased tumor resistance to osimertinib compared with the control group (Fig. 3G), confirming the critical role of CAMSAP3 in modulating osimertinib resistance. Here, CAMSAP3 is linked to neoplasm.